Connection

JAMES POOL to Blood Pressure

This is a "connection" page, showing publications JAMES POOL has written about Blood Pressure.
Connection Strength

0.566
  1. Clinical role of direct renin inhibition in hypertension. Am J Ther. 2012 May; 19(3):204-10.
    View in: PubMed
    Score: 0.068
  2. Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. J Clin Hypertens (Greenwich). 2011 May; 13(5):366-75.
    View in: PubMed
    Score: 0.062
  3. The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial. Clin Drug Investig. 2009; 29(12):791-802.
    View in: PubMed
    Score: 0.054
  4. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007 Jan; 20(1):11-20.
    View in: PubMed
    Score: 0.047
  5. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007 Jan; 29(1):61-73.
    View in: PubMed
    Score: 0.047
  6. Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. Am J Hypertens. 1999 Sep; 12(9 Pt 1):906-14.
    View in: PubMed
    Score: 0.028
  7. Sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: a dose-tolerability study. J Clin Pharmacol. 1999 May; 39(5):471-9.
    View in: PubMed
    Score: 0.028
  8. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens. 1999 Apr; 13(4):275-81.
    View in: PubMed
    Score: 0.027
  9. A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group. Am J Hypertens. 1998 Apr; 11(4 Pt 1):454-61.
    View in: PubMed
    Score: 0.026
  10. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 1998 Apr; 11(4 Pt 1):462-70.
    View in: PubMed
    Score: 0.026
  11. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol. 1997 Oct; 80(4):521-32.
    View in: PubMed
    Score: 0.025
  12. Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. Am J Hypertens. 1995 Feb; 8(2):133-45.
    View in: PubMed
    Score: 0.021
  13. Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose. Clin Sci (Lond). 2012 Feb; 122(4):193-202.
    View in: PubMed
    Score: 0.017
  14. Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: findings of the Fosinopril Study Group II. Clin Ther. 1990 Nov-Dec; 12(6):520-33.
    View in: PubMed
    Score: 0.015
  15. Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension. Am J Hypertens. 1988 Apr; 1(2):158-67.
    View in: PubMed
    Score: 0.013
  16. A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. Curr Med Res Opin. 2008 Apr; 24(4):1101-14.
    View in: PubMed
    Score: 0.013
  17. Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol. 1987; 9 Suppl 3:S36-42.
    View in: PubMed
    Score: 0.012
  18. Propylbutyldopamine. Mechanism of blood pressure lowering in hypertensive patients. Hypertension. 1984 Mar-Apr; 6(2 Pt 2):I40-5.
    View in: PubMed
    Score: 0.010
  19. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am J Cardiol. 2001 Mar 15; 87(6):727-31.
    View in: PubMed
    Score: 0.008
  20. Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension. J Clin Pharmacol. 1992 Apr; 32(4):351-9.
    View in: PubMed
    Score: 0.004
  21. Nicardipine as antihypertensive monotherapy: positive effects on quality of life. J Hum Hypertens. 1991 Jun; 5(3):205-13.
    View in: PubMed
    Score: 0.004
  22. Mitral valve prolapse with symptoms of beta-adrenergic hypersensitivity. Beta 2-adrenergic receptor supercoupling with desensitization on isoproterenol exposure. Am J Med. 1987 Feb; 82(2):193-201.
    View in: PubMed
    Score: 0.003
  23. Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist. Clin Pharmacol Ther. 1986 Dec; 40(6):694-7.
    View in: PubMed
    Score: 0.003
  24. Pharmacology of angiotensin converting enzyme inhibitors. A review. Am J Med. 1986 Oct 31; 81(4C):13-8.
    View in: PubMed
    Score: 0.003
  25. Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. J Cardiovasc Pharmacol. 1985 Jul-Aug; 7(4):767-76.
    View in: PubMed
    Score: 0.003
  26. A double-blind placebo-controlled cross-over study with lidoflazine (Clinium) in post-infarction patients. Acta Med Scand. 1976; 199(1-2):17-23.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.